Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.
4-Nitroquinoline-1-oxide
/ toxicity
Animals
Apoptosis
B7-H1 Antigen
/ metabolism
Carcinogenesis
/ chemically induced
Carcinogens
/ toxicity
Carcinoma, Squamous Cell
/ chemically induced
Cell Proliferation
Exosomes
/ drug effects
Female
Humans
Mice
Mice, Inbred C57BL
Mouth Neoplasms
/ chemically induced
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
10 07 2020
10 07 2020
Historique:
received:
26
04
2019
revised:
12
06
2019
accepted:
25
06
2019
pubmed:
28
6
2019
medline:
28
10
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Circulating tumor-derived exosomes (TEX) interact with a variety of cells in cancer-bearing hosts, leading to cellular reprogramming which promotes disease progression. To study TEX effects on the development of solid tumors, immunosuppressive exosomes carrying PD-L1 and FasL were isolated from supernatants of murine or human HNSCC cell lines. TEX were delivered (IV) to immunocompetent C57BL/6 mice bearing premalignant oral/esophageal lesions induced by the carcinogen, 4-nitroquinoline 1-oxide (4NQO). Progression of the premalignant oropharyngeal lesions to malignant tumors was monitored. A single TEX injection increased the number of developing tumors (6.2 versus 3.2 in control mice injected with phosphate-buffered saline; P < 0.0002) and overall tumor burden per mouse (P < 0.037). The numbers of CD4+ and CD8+ T lymphocytes infiltrating the developing tumors were coordinately reduced (P < 0.01) in mice injected with SCCVII-derived TEX relative to controls. Notably, TEX isolated from mouse or human tumors had similar effects on tumor development and immune cells. A single IV injection of TEX was sufficient to condition mice harboring premalignant OSCC lesions for accelerated tumor progression in concert with reduced immune cell migration to the tumor.
Identifiants
pubmed: 31245809
pii: 5524074
doi: 10.1093/carcin/bgz124
pmc: PMC7350555
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Carcinogens
0
4-Nitroquinoline-1-oxide
56-57-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-633Subventions
Organisme : NCI NIH HHS
ID : R01 CA168628
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oncogene. 2019 Apr;38(15):2830-2843
pubmed: 30546089
Front Oncol. 2018 Oct 12;8:445
pubmed: 30370252
Cancer Sci. 2017 Sep;108(9):1803-1810
pubmed: 28667694
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
Clin Cancer Res. 2006 Jul 1;12(13):3890-5
pubmed: 16818683
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Oncotarget. 2016 May 10;7(19):27033-43
pubmed: 27081032
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
J Vis Exp. 2018 May 6;(135):
pubmed: 29782011
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Future Oncol. 2017 Aug;13(18):1649-1663
pubmed: 28776423
J Immunol. 2005 Oct 15;175(8):5541-50
pubmed: 16210663
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7
pubmed: 23589885
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Clin Exp Immunol. 2017 Sep;189(3):259-267
pubmed: 28369805
Clin Cancer Res. 2013 Feb 15;19(4):889-99
pubmed: 23363813
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Sci Rep. 2017 Oct 31;7(1):14684
pubmed: 29089618
J Mol Histol. 2009 Jun;40(3):177-81
pubmed: 19685146
Semin Immunol. 2018 Feb;35:69-79
pubmed: 29289420
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
In Vivo. 2013 Jul-Aug;27(4):473-84
pubmed: 23812217
J Immunol Methods. 2012 May 31;379(1-2):1-14
pubmed: 22370428
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):301-13
pubmed: 14734483
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Cancer Res. 2015 Jun 1;75(11):2200-10
pubmed: 25832655
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Future Oncol. 2017 Dec;13(28):2583-2592
pubmed: 29198150
J Immunol. 2013 Dec 1;191(11):5515-23
pubmed: 24184557